SERUM LEVEL OF SOLUBLE VASCULAR ADHESION MOLECULE 1 IN RECTAL CANCER PATIENTS

Yıl 2011, Cilt: 8 Sayı: 2, - 4, 01.06.2011

Ahu Sarbay Kemik Ozgür Kemik Sevim Purisa İsmail Hasırcı Ahmet Cumhur Dulger Mine Adas Sefa Tuzun

Öz

Anahtar Kelimeler

-

SERUM LEVEL OF SOLUBLE VASCULAR ADHESION MOLECULE 1 IN RECTAL CANCER PATIENTS

Öz

-

Anahtar Kelimeler

-

Kaynakça

• Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorec- tal cancer patients. Eur J Cancer 2000;36:748-53.
• Benson AB, Ajani JA, Catalano RB, et al. Recommended guide-lines for the treatment-induced diarrhea. J Clin Oncol 2004;22:2918-26.
• Graziono F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003;14:1026-38.
• Negri FV, Campanini N, Camisa R, et al. Biological pre- dictive factors in rectal cancer treated preoperative ra- diotherapy or radiochemotherapy. Br J Cancer 2008;98: 143-7.
• Font A, Abad A, Monzo M, et al. Prognostic value K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001;44:549-57.
• Jernvall P, makine Mj, Karttunen TJ, Makela J, et al. Loss of heterozygosity at 18q21 is a indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J cancer 1999;79:903-8.
• Ferrara N. Vascular endothelial growth factor: basic sci- ence and clinical progress. Endocr Rev 2004;25:581-611.
• Ivarsson ML, Bergstrom M, Eriksson E, Risberg B, et al. Tissue markers as predictors of postoperative adhesions. Br J Surg 1998;85:1549-54.
• Edler D, Glimelius B, Hallstrom M, et al. Thymidylate syn- thase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil- based chemotherapy. J Clin Oncol 2002; 20:1721-28.
• Kim JG, Chae YS, Sohn KS, et al. Vascular endothelial growth factor gene polymorphisms associated with prog- nosis for patients with colorectal cancer. Clin Cancer Res 2008;14:62-6.
• Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003;63:812-6.
• Karayiannakis AJ, Syrigos KN, Zhar A, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect f tumor surgery. Surgery 2007;131:548-55.
• Kumar H, Heer K, Lee PW, et al. Preoperative serum Vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-85.
• Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radio- therapy. Cancer 2005;104:2517-21.
• Chin KF, Greenman J, Gardiner F, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000;83:1425-31.
• Tamura M, Oda M, Tsunezuka Y, Matsumoto I, Kawakami K, Watanabe G. Vascular endothelial growth factor expres- sion in metastatic pulmonary tumor from colorectal car- cinoma: utility as a prognostic factor. J Thorac Cardiovasc Surg 2004;128:517-22.
• Higashiyama A, Watanabe H, Okumura K, Yagita H. Involvement of tumor necrosis factor alpha and very late activation antigen 4/vascular cell adhesion molecule 1 interaction in surgical-stress-enhanced experimental me- tastases. Cancer Immunol Immunother 1996;42:231-6.
• Pigott R, Dillon LP, hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1, and VCAM-1 are present in the supernatants of cytokine activated cultured endothe- lial cells. Biochem BİOPHYS Commun 1992;187:584-9.